Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nitin Pal Kalia

Showing results (1-10 of 53) with videos related to

Pageof 6
Sort By:
Frontiers in Microbiology|May 16, 2022
Editorial: Approaches to Address Resistance, Drug Discovery, and Vaccine Development in <i>Mycobacterium tuberculosis</i>: Challenges and OpportunitiesSandeep Sharma, Divakar Sharma, Nitin Pal Kalia
Methods in Molecular Biology (Clifton, N.J.)|October 13, 2021
Turbidity-Based MIC Assay and Characterization of Spontaneous Drug Resistant Mutants in Mycobacterium ulceransSangeeta Susan Thomas, Nitin Pal Kalia, Kevin Pethe
Tuberculosis (Edinburgh, Scotland)|May 26, 2026
Delineating the potential of bioenergetics in drug discovery against MycobacteriumabscessusSwati Meshram, Puja Kumari Agnivesh, Nitin Pal Kalia
ACS Infectious Diseases|October 3, 2024
2-Aryl-Benzoimidazoles as Type II NADH Dehydrogenase Inhibitors of <i>Mycobacterium tuberculosis</i>Pallavi Saha, Shashikanta Sau, Nitin Pal Kalia, et al.
Bioorganic Chemistry|July 8, 2025
Targeting drug-resistant tuberculosis: Thioacetamide-substituted benzothiazoles as bactericidal agents inhibiting type II NADH dehydrogenasePallavi Saha, Shashikanta Sau, Nitin Pal Kalia, et al.
RSC Medicinal Chemistry|May 24, 2024
Antitubercular activity of 2-mercaptobenzothiazole derivatives targeting <i>Mycobacterium tuberculosis</i> type II NADH dehydrogenasePallavi Saha, Shashikanta Sau, Nitin Pal Kalia, et al.
Drug Discovery Today|January 13, 2023
Role of transcription termination factor Rho in anti-tuberculosis drug discoverySunil Kumar, Shashikanta Sau, Puja Kumari Agnivesh, et al.
Microbial Pathogenesis|July 6, 2025
Advancements in tuberculosis diagnostics: An updateMainak Ghosh, Monali Lahiri, Aman Dalal, et al.
Microbial Pathogenesis|November 9, 2024
Advancements and challenges in tuberculosis drug discovery: A comprehensive overviewPuja Kumari Agnivesh, Arnab Roy, Shashikanta Sau, et al.
Archives of Microbiology|May 25, 2026
Combination strategies targeting multiple ETC subunits as a rational approach for drug-resistant TB therapyShashikanta Sau, Puja Kumari Agnivesh, Arnab Roy, et al.
Pageof 6

Showing results (1-10 of 53) with videos related to

Sort By:
Pageof 6
Frontiers in Microbiology|May 16, 2022
Editorial: Approaches to Address Resistance, Drug Discovery, and Vaccine Development in <i>Mycobacterium tuberculosis</i>: Challenges and OpportunitiesSandeep Sharma, Divakar Sharma, Nitin Pal Kalia
Methods in Molecular Biology (Clifton, N.J.)|October 13, 2021
Turbidity-Based MIC Assay and Characterization of Spontaneous Drug Resistant Mutants in Mycobacterium ulceransSangeeta Susan Thomas, Nitin Pal Kalia, Kevin Pethe
Tuberculosis (Edinburgh, Scotland)|May 26, 2026
Delineating the potential of bioenergetics in drug discovery against MycobacteriumabscessusSwati Meshram, Puja Kumari Agnivesh, Nitin Pal Kalia
ACS Infectious Diseases|October 3, 2024
2-Aryl-Benzoimidazoles as Type II NADH Dehydrogenase Inhibitors of <i>Mycobacterium tuberculosis</i>Pallavi Saha, Shashikanta Sau, Nitin Pal Kalia, et al.
Bioorganic Chemistry|July 8, 2025
Targeting drug-resistant tuberculosis: Thioacetamide-substituted benzothiazoles as bactericidal agents inhibiting type II NADH dehydrogenasePallavi Saha, Shashikanta Sau, Nitin Pal Kalia, et al.
RSC Medicinal Chemistry|May 24, 2024
Antitubercular activity of 2-mercaptobenzothiazole derivatives targeting <i>Mycobacterium tuberculosis</i> type II NADH dehydrogenasePallavi Saha, Shashikanta Sau, Nitin Pal Kalia, et al.
Drug Discovery Today|January 13, 2023
Role of transcription termination factor Rho in anti-tuberculosis drug discoverySunil Kumar, Shashikanta Sau, Puja Kumari Agnivesh, et al.
Microbial Pathogenesis|July 6, 2025
Advancements in tuberculosis diagnostics: An updateMainak Ghosh, Monali Lahiri, Aman Dalal, et al.
Microbial Pathogenesis|November 9, 2024
Advancements and challenges in tuberculosis drug discovery: A comprehensive overviewPuja Kumari Agnivesh, Arnab Roy, Shashikanta Sau, et al.
Archives of Microbiology|May 25, 2026
Combination strategies targeting multiple ETC subunits as a rational approach for drug-resistant TB therapyShashikanta Sau, Puja Kumari Agnivesh, Arnab Roy, et al.
Pageof 6